25 XP   0   0   10

Galapagos NV
Buy, Hold or Sell?

Let's analyse Galapagos NV together

PenkeI guess you are interested in Galapagos NV. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Galapagos NV. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Galapagos NV

I send you an email if I find something interesting about Galapagos NV.

Quick analysis of Galapagos NV (30 sec.)










What can you expect buying and holding a share of Galapagos NV? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$43.93
Expected worth in 1 year
$48.95
How sure are you?
52.6%

+ What do you gain per year?

Total Gains per Share
$5.01
Return On Investment
19.1%

For what price can you sell your share?

Current Price per Share
$26.20
Expected price per share
$26.20 - $26.20
How sure are you?
50%

1. Valuation of Galapagos NV (5 min.)




Live pricePrice per Share (EOD)

$26.20

Intrinsic Value Per Share

$-54.93 - $-62.80

Total Value Per Share

$-10.99 - $-18.87

2. Growth of Galapagos NV (5 min.)




Is Galapagos NV growing?

Current yearPrevious yearGrowGrow %
How rich?$2.8b$2.6b$117m4.3%

How much money is Galapagos NV making?

Current yearPrevious yearGrowGrow %
Making money$75.6m-$49.2m$124.8m165.1%
Net Profit Margin23.5%-50.7%--

How much money comes from the company's main activities?

3. Financial Health of Galapagos NV (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#25 / 996

Most Revenue
#167 / 996

Most Profit
#29 / 996

What can you expect buying and holding a share of Galapagos NV? (5 min.)

Welcome investor! Galapagos NV's management wants to use your money to grow the business. In return you get a share of Galapagos NV.

What can you expect buying and holding a share of Galapagos NV?

First you should know what it really means to hold a share of Galapagos NV. And how you can make/lose money.

Speculation

The Price per Share of Galapagos NV is $26.20. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Galapagos NV.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Galapagos NV, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $43.93. Based on the TTM, the Book Value Change Per Share is $1.25 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.21 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Galapagos NV.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps1.495.7%1.154.4%-0.75-2.9%-0.05-0.2%-0.16-0.6%
Usd Book Value Change Per Share1.515.8%1.254.8%-0.21-0.8%1.305.0%1.114.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share1.515.8%1.254.8%-0.21-0.8%1.305.0%1.114.2%
Usd Price Per Share35.52-37.05-46.79-75.03-51.14-
Price to Earnings Ratio5.98-38.74-3.68-13.18-1.77-
Price-to-Total Gains Ratio23.54-60.83-65.52-233.37-139.66-
Price to Book Ratio0.81-0.90-1.18-1.82-2.12-
Price-to-Total Gains Ratio23.54-60.83-65.52-233.37-139.66-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share26.2
Number of shares38
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share1.251.30
Usd Total Gains Per Share1.251.30
Gains per Quarter (38 shares)47.6349.57
Gains per Year (38 shares)190.53198.28
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101911810198188
203813720397386
305725630595584
407627540793782
509539450991980
6011431136011901178
7013341327013881376
8015241518015861574
9017151709017851772
10019051900019831970

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%7.05.00.058.3%10.010.00.050.0%14.024.00.036.8%14.025.00.035.9%
Book Value Change Per Share4.00.00.0100.0%9.03.00.075.0%12.08.00.060.0%20.017.01.052.6%21.017.01.053.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.038.00.0%0.00.039.00.0%
Total Gains per Share4.00.00.0100.0%9.03.00.075.0%12.08.00.060.0%20.017.01.052.6%21.017.01.053.8%

Fundamentals of Galapagos NV

About Galapagos NV

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Fundamental data was last updated by Penke on 2024-05-15 02:46:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Galapagos NV.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Galapagos NV earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Galapagos NV to the Biotechnology industry mean.
  • A Net Profit Margin of 144.5% means that $1.45 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Galapagos NV:

  • The MRQ is 144.5%. The company is making a huge profit. +2
  • The TTM is 23.5%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ144.5%TTM23.5%+121.0%
TTM23.5%YOY-50.7%+74.2%
TTM23.5%5Y-31.6%+55.1%
5Y-31.6%10Y-70.4%+38.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ144.5%-177.0%+321.5%
TTM23.5%-223.7%+247.2%
YOY-50.7%-256.7%+206.0%
5Y-31.6%-431.4%+399.8%
10Y-70.4%-551.3%+480.9%
1.1.2. Return on Assets

Shows how efficient Galapagos NV is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Galapagos NV to the Biotechnology industry mean.
  • 2.2% Return on Assets means that Galapagos NV generated $0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Galapagos NV:

  • The MRQ is 2.2%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.7%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ2.2%TTM1.7%+0.5%
TTM1.7%YOY-1.0%+2.8%
TTM1.7%5Y-0.2%+2.0%
5Y-0.2%10Y-1.3%+1.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.2%-11.9%+14.1%
TTM1.7%-11.7%+13.4%
YOY-1.0%-10.8%+9.8%
5Y-0.2%-13.0%+12.8%
10Y-1.3%-14.2%+12.9%
1.1.3. Return on Equity

Shows how efficient Galapagos NV is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Galapagos NV to the Biotechnology industry mean.
  • 3.4% Return on Equity means Galapagos NV generated $0.03 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Galapagos NV:

  • The MRQ is 3.4%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.7%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ3.4%TTM2.7%+0.7%
TTM2.7%YOY-2.0%+4.7%
TTM2.7%5Y-0.4%+3.1%
5Y-0.4%10Y-1.7%+1.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.4%-15.1%+18.5%
TTM2.7%-14.7%+17.4%
YOY-2.0%-13.3%+11.3%
5Y-0.4%-17.6%+17.2%
10Y-1.7%-19.1%+17.4%

1.2. Operating Efficiency of Galapagos NV.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Galapagos NV is operating .

  • Measures how much profit Galapagos NV makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Galapagos NV to the Biotechnology industry mean.
  • An Operating Margin of -21.2% means the company generated $-0.21  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Galapagos NV:

  • The MRQ is -21.2%. The company is operating very inefficient. -2
  • The TTM is -5.1%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-21.2%TTM-5.1%-16.1%
TTM-5.1%YOY-51.6%+46.5%
TTM-5.1%5Y-35.7%+30.6%
5Y-35.7%10Y-88.4%+52.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-21.2%-348.2%+327.0%
TTM-5.1%-232.7%+227.6%
YOY-51.6%-266.9%+215.3%
5Y-35.7%-412.2%+376.5%
10Y-88.4%-516.7%+428.3%
1.2.2. Operating Ratio

Measures how efficient Galapagos NV is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.68 means that the operating costs are $1.68 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Galapagos NV:

  • The MRQ is 1.681. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.051. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.681TTM1.051+0.630
TTM1.051YOY1.525-0.474
TTM1.0515Y1.636-0.585
5Y1.63610Y2.925-1.289
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6813.097-1.416
TTM1.0513.332-2.281
YOY1.5253.564-2.039
5Y1.6365.224-3.588
10Y2.9256.637-3.712

1.3. Liquidity of Galapagos NV.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Galapagos NV is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 9.91 means the company has $9.91 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Galapagos NV:

  • The MRQ is 9.907. The company is very able to pay all its short-term debts. +2
  • The TTM is 9.080. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ9.907TTM9.080+0.826
TTM9.080YOY8.168+0.913
TTM9.0805Y8.696+0.385
5Y8.69610Y7.871+0.824
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.9073.798+6.109
TTM9.0804.146+4.934
YOY8.1685.212+2.956
5Y8.6966.093+2.603
10Y7.8716.441+1.430
1.3.2. Quick Ratio

Measures if Galapagos NV is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Galapagos NV to the Biotechnology industry mean.
  • A Quick Ratio of 18.67 means the company can pay off $18.67 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Galapagos NV:

  • The MRQ is 18.666. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 17.215. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ18.666TTM17.215+1.451
TTM17.215YOY14.914+2.301
TTM17.2155Y14.112+3.103
5Y14.11210Y10.463+3.649
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ18.6663.165+15.501
TTM17.2153.776+13.439
YOY14.9145.140+9.774
5Y14.1125.839+8.273
10Y10.4636.367+4.096

1.4. Solvency of Galapagos NV.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Galapagos NV assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Galapagos NV to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.34 means that Galapagos NV assets are financed with 33.6% credit (debt) and the remaining percentage (100% - 33.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Galapagos NV:

  • The MRQ is 0.336. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.384. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.336TTM0.384-0.047
TTM0.384YOY0.462-0.078
TTM0.3845Y0.463-0.079
5Y0.46310Y0.351+0.111
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3360.340-0.004
TTM0.3840.341+0.043
YOY0.4620.279+0.183
5Y0.4630.366+0.097
10Y0.3510.380-0.029
1.4.2. Debt to Equity Ratio

Measures if Galapagos NV is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Galapagos NV to the Biotechnology industry mean.
  • A Debt to Equity ratio of 50.7% means that company has $0.51 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Galapagos NV:

  • The MRQ is 0.507. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.628. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.507TTM0.628-0.122
TTM0.628YOY0.858-0.230
TTM0.6285Y0.903-0.275
5Y0.90310Y0.620+0.283
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5070.388+0.119
TTM0.6280.415+0.213
YOY0.8580.356+0.502
5Y0.9030.443+0.460
10Y0.6200.469+0.151

2. Market Valuation of Galapagos NV

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Galapagos NV generates.

  • Above 15 is considered overpriced but always compare Galapagos NV to the Biotechnology industry mean.
  • A PE ratio of 5.98 means the investor is paying $5.98 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Galapagos NV:

  • The EOD is 4.409. Based on the earnings, the company is cheap. +2
  • The MRQ is 5.978. Based on the earnings, the company is cheap. +2
  • The TTM is 38.740. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD4.409MRQ5.978-1.569
MRQ5.978TTM38.740-32.762
TTM38.740YOY3.678+35.062
TTM38.7405Y13.180+25.560
5Y13.18010Y1.766+11.414
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.409-2.289+6.698
MRQ5.978-2.558+8.536
TTM38.740-2.723+41.463
YOY3.678-3.900+7.578
5Y13.180-6.368+19.548
10Y1.766-6.544+8.310
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Galapagos NV:

  • The EOD is -3.480. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -4.717. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -5.624. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.480MRQ-4.717+1.238
MRQ-4.717TTM-5.624+0.906
TTM-5.624YOY-5.685+0.061
TTM-5.6245Y-10.542+4.919
5Y-10.54210Y-10.400-0.142
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.480-3.247-0.233
MRQ-4.717-3.308-1.409
TTM-5.624-3.522-2.102
YOY-5.685-5.154-0.531
5Y-10.542-8.005-2.537
10Y-10.400-8.608-1.792
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Galapagos NV is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.81 means the investor is paying $0.81 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Galapagos NV:

  • The EOD is 0.596. Based on the equity, the company is cheap. +2
  • The MRQ is 0.809. Based on the equity, the company is cheap. +2
  • The TTM is 0.901. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.596MRQ0.809-0.212
MRQ0.809TTM0.901-0.092
TTM0.901YOY1.181-0.280
TTM0.9015Y1.821-0.920
5Y1.82110Y2.116-0.295
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.5961.996-1.400
MRQ0.8092.027-1.218
TTM0.9012.073-1.172
YOY1.1812.696-1.515
5Y1.8213.727-1.906
10Y2.1164.109-1.993
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Galapagos NV compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.5091.253+20%-0.213+114%1.304+16%1.109+36%
Book Value Per Share--43.93241.337+6%39.561+11%39.447+11%26.072+69%
Current Ratio--9.9079.080+9%8.168+21%8.696+14%7.871+26%
Debt To Asset Ratio--0.3360.384-12%0.462-27%0.463-27%0.351-4%
Debt To Equity Ratio--0.5070.628-19%0.858-41%0.903-44%0.620-18%
Dividend Per Share----0%-0%-0%-0%
Eps--1.4851.147+29%-0.747+150%-0.047+103%-0.156+111%
Free Cash Flow Per Share---1.882-1.708-9%-2.144+14%0.816-331%0.310-708%
Free Cash Flow To Equity Per Share---1.900-1.730-9%-2.150+13%1.836-203%1.370-239%
Gross Profit Margin--0.968-0.236+124%1.119-14%0.818+18%0.908+7%
Intrinsic Value_10Y_max---62.805--------
Intrinsic Value_10Y_min---54.926--------
Intrinsic Value_1Y_max---7.488--------
Intrinsic Value_1Y_min---7.356--------
Intrinsic Value_3Y_max---21.588--------
Intrinsic Value_3Y_min---20.628--------
Intrinsic Value_5Y_max---34.590--------
Intrinsic Value_5Y_min---32.184--------
Market Cap1726504020.000-36%2340664992.0002441322812.250-4%3083490051.750-24%4972307941.100-53%3384618687.816-31%
Net Profit Margin--1.4450.235+514%-0.507+135%-0.316+122%-0.704+149%
Operating Margin---0.212-0.051-76%-0.516+143%-0.357+68%-0.884+316%
Operating Ratio--1.6811.051+60%1.525+10%1.636+3%2.925-43%
Pb Ratio0.596-36%0.8090.901-10%1.181-32%1.821-56%2.116-62%
Pe Ratio4.409-36%5.97838.740-85%3.678+63%13.180-55%1.766+238%
Price Per Share26.200-36%35.52037.048-4%46.793-24%75.034-53%51.140-31%
Price To Free Cash Flow Ratio-3.480+26%-4.717-5.624+19%-5.685+21%-10.542+123%-10.400+120%
Price To Total Gains Ratio17.362-36%23.53860.831-61%65.521-64%233.370-90%139.657-83%
Quick Ratio--18.66617.215+8%14.914+25%14.112+32%10.463+78%
Return On Assets--0.0220.017+30%-0.010+146%-0.002+110%-0.013+159%
Return On Equity--0.0340.027+25%-0.020+158%-0.004+111%-0.017+149%
Total Gains Per Share--1.5091.253+20%-0.213+114%1.304+16%1.109+36%
Usd Book Value--2895008000.0002724020500.000+6%2606969750.000+11%2607313900.000+11%1735288947.368+67%
Usd Book Value Change Per Share--1.5091.253+20%-0.213+114%1.304+16%1.109+36%
Usd Book Value Per Share--43.93241.337+6%39.561+11%39.447+11%26.072+69%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--1.4851.147+29%-0.747+150%-0.047+103%-0.156+111%
Usd Free Cash Flow---124043000.000-112533500.000-9%-141252250.000+14%53540000.000-332%20609815.789-702%
Usd Free Cash Flow Per Share---1.882-1.708-9%-2.144+14%0.816-331%0.310-708%
Usd Free Cash Flow To Equity Per Share---1.900-1.730-9%-2.150+13%1.836-203%1.370-239%
Usd Market Cap1726504020.000-36%2340664992.0002441322812.250-4%3083490051.750-24%4972307941.100-53%3384618687.816-31%
Usd Price Per Share26.200-36%35.52037.048-4%46.793-24%75.034-53%51.140-31%
Usd Profit--97888700.00075600087.500+29%-49224822.500+150%-6848574.250+107%-11265612.105+112%
Usd Revenue--67738720.00033441870.000+103%148590750.000-54%140088256.000-52%91955634.474-26%
Usd Total Gains Per Share--1.5091.253+20%-0.213+114%1.304+16%1.109+36%
 EOD+3 -5MRQTTM+22 -12YOY+25 -95Y+22 -1210Y+22 -12

3.2. Fundamental Score

Let's check the fundamental score of Galapagos NV based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-154.409
Price to Book Ratio (EOD)Between0-10.596
Net Profit Margin (MRQ)Greater than01.445
Operating Margin (MRQ)Greater than0-0.212
Quick Ratio (MRQ)Greater than118.666
Current Ratio (MRQ)Greater than19.907
Debt to Asset Ratio (MRQ)Less than10.336
Debt to Equity Ratio (MRQ)Less than10.507
Return on Equity (MRQ)Greater than0.150.034
Return on Assets (MRQ)Greater than0.050.022
Total7/10 (70.0%)

3.3. Technical Score

Let's check the technical score of Galapagos NV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than500.686
Ma 20Greater thanMa 5026.200
Ma 50Greater thanMa 10030.487
Ma 100Greater thanMa 20032.705
OpenGreater thanClose26.200
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets4,361,379
Total Liabilities1,466,371
Total Stockholder Equity2,895,008
 As reported
Total Liabilities 1,466,371
Total Stockholder Equity+ 2,895,008
Total Assets = 4,361,379

Assets

Total Assets4,361,379
Total Current Assets3,786,470
Long-term Assets574,909
Total Current Assets
Cash And Cash Equivalents 73,372
Short-term Investments 3,484,560
Net Receivables 92,047
Inventory 80,558
Other Current Assets 55,933
Total Current Assets  (as reported)3,786,470
Total Current Assets  (calculated)3,786,470
+/-0
Long-term Assets
Property Plant Equipment 125,059
Goodwill 69,715
Intangible Assets 125,998
Long-term Assets Other 65,516
Long-term Assets  (as reported)574,909
Long-term Assets  (calculated)386,288
+/- 188,621

Liabilities & Shareholders' Equity

Total Current Liabilities382,214
Long-term Liabilities1,084,157
Total Stockholder Equity2,895,008
Total Current Liabilities
Short-term Debt 4,140
Accounts payable 145,551
Other Current Liabilities 62
Total Current Liabilities  (as reported)382,214
Total Current Liabilities  (calculated)149,753
+/- 232,461
Long-term Liabilities
Capital Lease Obligations 7,977
Long-term Liabilities Other 42,887
Long-term Liabilities  (as reported)1,084,157
Long-term Liabilities  (calculated)50,864
+/- 1,033,293
Total Stockholder Equity
Common Stock293,937
Retained Earnings -133,080
Accumulated Other Comprehensive Income -2,843
Other Stockholders Equity 2,736,994
Total Stockholder Equity (as reported)2,895,008
Total Stockholder Equity (calculated)2,895,008
+/-0
Other
Capital Stock293,937
Cash and Short Term Investments 3,557,932
Common Stock Shares Outstanding 65,897
Current Deferred Revenue232,461
Liabilities and Stockholders Equity 4,361,379
Net Debt -65,395
Net Invested Capital 2,895,008
Net Working Capital 3,404,256
Short Long Term Debt Total 7,977



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-06-302013-12-312013-06-302012-12-312012-06-302011-12-312011-06-302010-12-312010-06-302009-12-312009-06-302008-12-31
> Total Assets 
118,824
106,216
143,709
139,736
193,961
152,989
161,055
243,338
235,329
276,228
287,374
304,980
270,467
0
488,263
461,048
442,514
1,079,287
1,066,524
1,043,092
1,083,338
1,072,814
1,368,355
1,331,373
1,286,274
1,229,864
1,204,348
1,485,551
1,439,496
1,400,200
1,357,848
5,851,752
6,068,609
5,992,406
5,851,564
5,721,087
5,717,731
5,615,059
5,430,617
5,331,987
5,193,160
5,100,315
5,040,085
4,972,070
4,734,351
4,632,172
4,522,340
4,451,336
4,357,396
4,361,379
4,361,3794,357,3964,451,3364,522,3404,632,1724,734,3514,972,0705,040,0855,100,3155,193,1605,331,9875,430,6175,615,0595,717,7315,721,0875,851,5645,992,4066,068,6095,851,7521,357,8481,400,2001,439,4961,485,5511,204,3481,229,8641,286,2741,331,3731,368,3551,072,8141,083,3381,043,0921,066,5241,079,287442,514461,048488,2630270,467304,980287,374276,228235,329243,338161,055152,989193,961139,736143,709106,216118,824
   > Total Current Assets 
59,849
44,623
84,686
58,251
109,223
67,403
65,562
143,735
132,727
168,039
176,653
254,894
213,603
0
422,245
397,561
374,470
1,007,664
992,267
962,967
1,007,232
992,122
1,284,957
1,243,839
1,197,647
1,135,735
1,107,881
1,390,400
1,328,851
1,259,244
1,208,604
5,651,013
5,865,927
5,780,264
5,622,005
5,463,769
5,369,347
5,310,922
5,129,494
5,015,997
4,861,854
4,750,700
4,533,192
4,462,397
4,236,850
4,155,294
4,032,147
3,956,092
3,861,589
3,786,470
3,786,4703,861,5893,956,0924,032,1474,155,2944,236,8504,462,3974,533,1924,750,7004,861,8545,015,9975,129,4945,310,9225,369,3475,463,7695,622,0055,780,2645,865,9275,651,0131,208,6041,259,2441,328,8511,390,4001,107,8811,135,7351,197,6471,243,8391,284,957992,1221,007,232962,967992,2671,007,664374,470397,561422,2450213,603254,894176,653168,039132,727143,73565,56267,403109,22358,25184,68644,62359,849
       Cash And Cash Equivalents 
27,316
18,745
47,391
27,165
40,397
49,845
32,555
122,613
94,647
136,709
141,481
231,531
187,712
0
397,477
366,545
340,314
978,334
960,481
930,807
973,241
953,385
1,262,061
1,218,856
1,151,211
1,108,186
1,066,766
1,343,668
1,290,796
1,222,901
1,147,923
5,599,787
1,861,616
2,743,573
2,384,220
2,087,797
2,135,187
2,553,950
2,642,639
2,834,378
2,233,368
1,254,279
972,796
675,519
508,117
124,135
98,024
159,375
166,803
73,372
73,372166,803159,37598,024124,135508,117675,519972,7961,254,2792,233,3682,834,3782,642,6392,553,9502,135,1872,087,7972,384,2202,743,5731,861,6165,599,7871,147,9231,222,9011,290,7961,343,6681,066,7661,108,1861,151,2111,218,8561,262,061953,385973,241930,807960,481978,334340,314366,545397,4770187,712231,531141,481136,70994,647122,61332,55549,84540,39727,16547,39118,74527,316
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,919,216
2,978,805
3,182,276
3,220,805
3,026,278
2,560,743
2,363,969
2,039,787
2,469,809
3,389,098
3,456,184
3,686,557
3,585,945
3,865,915
3,776,913
3,652,333
3,517,698
3,484,560
3,484,5603,517,6983,652,3333,776,9133,865,9153,585,9453,686,5573,456,1843,389,0982,469,8092,039,7872,363,9692,560,7433,026,2783,220,8053,182,2762,978,8053,919,21600000000000000000000000000000000
       Net Receivables 
26,616
20,131
31,984
26,173
63,484
14,304
30,010
16,083
33,242
26,540
31,979
20,061
13,795
0
11,801
19,163
16,057
15,075
17,625
18,127
23,478
26,164
15,642
17,740
41,788
20,086
33,762
37,006
33,533
26,992
53,711
42,388
80,109
49,180
45,190
139,299
173,400
180,347
113,600
126,802
128,601
78,521
64,058
54,374
77,344
67,569
67,576
73,044
65,655
92,047
92,04765,65573,04467,57667,56977,34454,37464,05878,521128,601126,802113,600180,347173,400139,29945,19049,18080,10942,38853,71126,99233,53337,00633,76220,08641,78817,74015,64226,16423,47818,12717,62515,07516,05719,16311,801013,79520,06131,97926,54033,24216,08330,01014,30463,48426,17331,98420,13126,616
       Inventory 
3,574
4,143
1,816
1,774
1,437
1,061
502
517
204
270
249
297
281
0
361
344
325
347
322
326
300
324
318
304
279
293
267
280
276
0
0
0
255
0
0
0
355
0
0
0
20,569
18,398
27,008
25,510
52,925
51,770
48,868
55,605
73,978
80,558
80,55873,97855,60548,86851,77052,92525,51027,00818,39820,56900035500025500027628026729327930431832430032632234732534436102812972492702045175021,0611,4371,7741,8164,1433,574
       Other Current Assets 
2,343
1,604
3,495
3,139
3,905
2,193
2,495
4,522
4,634
4,520
5,091
3,005
11,815
0
5,751
4,653
-1
5,642
6,981
6,848
1
8,215
6,936
6,939
1
7,170
7,086
7,432
4,246
9,351
6,970
8,838
4,731
8,706
10,319
15,868
34,127
15,882
9,286
15,030
-1
10,404
13,146
20,437
2
27,897
40,766
15,735
37,455
55,933
55,93337,45515,73540,76627,897220,43713,14610,404-115,0309,28615,88234,12715,86810,3198,7064,7318,8386,9709,3514,2467,4327,0867,17016,9396,9368,21516,8486,9815,642-14,6535,751011,8153,0055,0914,5204,6344,5222,4952,1933,9053,1393,4951,6042,343
   > Long-term Assets 
58,975
61,593
59,023
81,485
84,738
85,586
95,493
99,601
102,602
108,189
110,721
50,086
56,864
0
66,018
63,487
68,044
71,624
74,257
80,127
76,107
80,692
83,398
0
88,627
94,129
96,467
95,151
110,645
140,956
149,244
200,739
202,682
212,142
229,559
257,318
348,384
304,136
301,123
315,990
331,306
349,615
506,893
509,673
497,501
476,877
490,193
495,244
495,807
574,909
574,909495,807495,244490,193476,877497,501509,673506,893349,615331,306315,990301,123304,136348,384257,318229,559212,142202,682200,739149,244140,956110,64595,15196,46794,12988,627083,39880,69276,10780,12774,25771,62468,04463,48766,018056,86450,086110,721108,189102,60299,60195,49385,58684,73881,48559,02361,59358,975
       Property Plant Equipment 
20,293
20,542
19,285
20,473
23,886
20,310
19,523
19,253
18,099
17,273
19,525
10,761
10,091
0
11,178
12,577
13,783
14,110
15,091
15,032
14,959
15,064
15,506
15,279
16,692
16,971
17,854
18,113
23,138
49,542
51,180
61,883
66,054
66,979
73,786
94,661
103,379
111,294
111,900
123,637
137,513
145,896
148,866
150,394
154,253
134,888
134,728
136,803
126,321
125,059
125,059126,321136,803134,728134,888154,253150,394148,866145,896137,513123,637111,900111,294103,37994,66173,78666,97966,05461,88351,18049,54223,13818,11317,85416,97116,69215,27915,50615,06414,95915,03215,09114,11013,78312,57711,178010,09110,76119,52517,27318,09919,25319,52320,31023,88620,47319,28520,54220,293
       Goodwill 
33,751
33,751
33,751
42,710
42,380
38,880
38,880
38,314
37,667
39,240
39,239
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
174,288
174,994
69,813
69,672
69,678
69,863
69,557
69,715
69,71569,55769,86369,67869,67269,813174,994174,288000000000000000000000000000000039,23939,24037,66738,31438,88038,88042,38042,71033,75133,75133,751
       Long Term Investments 
0
0
0
0
0
0
0
0
46,524
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,106
0
0
0
6,000
0
0
0
0
0
0
0
8,951
0
0
0
0
0
0
0
0
0
0
0
13,575
0
013,575000000000008,95100000006,0000002,10600000000000000046,52400000000
       Intangible Assets 
4,159
4,209
3,480
15,538
13,534
11,188
10,614
9,821
9,426
8,528
7,833
1,862
2,016
0
1,575
1,517
1,552
1,382
1,226
1,150
1,025
963
859
747
2,498
2,555
1,403
2,058
3,631
6,497
7,191
23,492
24,925
33,856
39,254
41,114
67,566
65,738
63,072
59,623
60,103
0
32,346
38,493
146,353
140,914
136,470
132,313
127,906
125,998
125,998127,906132,313136,470140,914146,35338,49332,346060,10359,62363,07265,73867,56641,11439,25433,85624,92523,4927,1916,4973,6312,0581,4032,5552,4987478599631,0251,1501,2261,3821,5521,5171,57502,0161,8627,8338,5289,4269,82110,61411,18813,53415,5383,4804,2094,159
       Long-term Assets Other 
772
2,302
807
1,064
1,280
14,041
24,310
28,676
35,705
41,252
39,346
37,248
44,464
0
51,504
47,632
50,983
54,406
56,184
62,189
58,166
62,708
65,076
0
67,459
72,624
75,230
72,455
81,362
82,406
88,357
95,958
96,223
107,101
112,312
117,687
164,013
122,664
121,700
128,259
129,658
7,881
8,388
7,832
5,778
5,702
17,927
16,912
157,322
65,516
65,516157,32216,91217,9275,7025,7787,8328,3887,881129,658128,259121,700122,664164,013117,687112,312107,10196,22395,95888,35782,40681,36272,45575,23072,62467,459065,07662,70858,16662,18956,18454,40650,98347,63251,504044,46437,24839,34641,25235,70528,67624,31014,0411,2801,0648072,302772
> Total Liabilities 
34,500
26,975
34,832
36,555
45,454
34,697
42,679
130,998
116,882
108,216
120,237
79,965
64,332
0
44,808
42,258
77,515
350,742
336,724
334,271
324,637
324,664
299,329
294,441
274,291
330,519
318,689
297,329
225,247
224,445
214,481
3,316,471
3,192,951
3,152,365
3,078,301
3,009,004
3,047,376
2,913,597
2,767,144
2,714,604
2,549,798
2,453,726
2,393,187
2,281,719
2,208,325
2,067,568
1,938,392
1,829,776
1,561,830
1,466,371
1,466,3711,561,8301,829,7761,938,3922,067,5682,208,3252,281,7192,393,1872,453,7262,549,7982,714,6042,767,1442,913,5973,047,3763,009,0043,078,3013,152,3653,192,9513,316,471214,481224,445225,247297,329318,689330,519274,291294,441299,329324,664324,637334,271336,724350,74277,51542,25844,808064,33279,965120,237108,216116,882130,99842,67934,69745,45436,55534,83226,97534,500
   > Total Current Liabilities 
29,751
22,787
31,344
28,053
38,223
27,818
35,360
124,367
109,014
99,294
112,559
75,977
60,356
0
40,299
37,251
72,412
104,736
111,549
129,826
103,791
127,984
130,678
154,531
171,699
223,631
246,586
269,102
219,905
199,450
188,712
631,300
571,793
622,626
618,538
601,744
635,274
605,362
576,985
575,494
566,474
562,896
550,725
532,207
522,538
522,904
475,073
444,036
428,223
382,214
382,214428,223444,036475,073522,904522,538532,207550,725562,896566,474575,494576,985605,362635,274601,744618,538622,626571,793631,300188,712199,450219,905269,102246,586223,631171,699154,531130,678127,984103,791129,826111,549104,73672,41237,25140,299060,35675,977112,55999,294109,014124,36735,36027,81838,22328,05331,34422,78729,751
       Short-term Debt 
546
255
520
419
378
396
425
406
240
246
226
114
52
0
51
51
52
52
53
53
54
50
37
23
9
1,805
0
0
2,065
4,580
5,141
5,251
5,826
6,210
6,872
7,116
6,401
6,475
6,480
7,262
7,204
7,065
7,179
6,926
7,209
5,782
6,210
5,678
4,652
4,140
4,1404,6525,6786,2105,7827,2096,9267,1797,0657,2047,2626,4806,4756,4017,1166,8726,2105,8265,2515,1414,5802,065001,805923375054535352525151052114226246240406425396378419520255546
       Short Long Term Debt 
0
0
0
0
0
0
0
0
316
0
0
0
0
0
0
0
0
0
0
0
63
50
37
23
11
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000011233750630000000000031600000000
       Accounts payable 
13,425
11,850
15,130
12,556
22,012
16,107
18,068
15,739
22,093
20,449
29,365
23,047
30,007
0
32,823
32,775
29,113
24,223
22,673
27,749
31,209
46,964
36,686
48,437
47,122
55,657
69,141
80,721
68,038
69,880
86,216
156,254
142,510
169,477
179,432
157,259
171,316
161,867
151,721
145,260
134,304
134,668
160,746
154,745
133,298
155,949
131,074
121,129
134,653
145,551
145,551134,653121,129131,074155,949133,298154,745160,746134,668134,304145,260151,721161,867171,316157,259179,432169,477142,510156,25486,21669,88068,03880,72169,14155,65747,12248,43736,68646,96431,20927,74922,67324,22329,11332,77532,823030,00723,04729,36520,44922,09315,73918,06816,10722,01212,55615,13011,85013,425
       Other Current Liabilities 
15,780
2,014
15,694
15,078
15,833
11,315
16,867
108,222
3,073
3,082
3,989
52,816
3,271
0
3,255
3,146
3,441
6,390
5,724
2,851
1,701
3,888
4,124
104,680
4,048
1,806
1,723
1,722
2,066
2,336
1,030
1,031
9,159
27,868
28,578
15,394
14,398
2,277
713
593
5,100
3,039
724
873
16,400
9,857
7,154
1,764
32,648
62
6232,6481,7647,1549,85716,4008737243,0395,1005937132,27714,39815,39428,57827,8689,1591,0311,0302,3362,0661,7221,7231,8064,048104,6804,1243,8881,7012,8515,7246,3903,4413,1463,25503,27152,8163,9893,0823,073108,22216,86711,31515,83315,07815,6942,01415,780
   > Long-term Liabilities 
4,749
4,188
3,488
8,502
7,231
6,879
7,319
6,631
7,868
8,922
7,678
3,988
3,976
0
4,509
5,007
5,103
246,006
225,175
204,445
220,846
196,680
168,651
0
102,592
106,888
72,103
28,227
5,342
24,995
25,769
2,685,171
2,621,158
2,529,739
2,459,763
2,407,260
2,412,102
2,308,235
2,190,159
2,139,110
1,983,324
1,890,830
1,842,462
1,749,512
1,685,787
1,544,664
1,463,319
1,385,740
1,133,607
1,084,157
1,084,1571,133,6071,385,7401,463,3191,544,6641,685,7871,749,5121,842,4621,890,8301,983,3242,139,1102,190,1592,308,2352,412,1022,407,2602,459,7632,529,7392,621,1582,685,17125,76924,9955,34228,22772,103106,888102,5920168,651196,680220,846204,445225,175246,0065,1035,0074,50903,9763,9887,6788,9227,8686,6317,3196,8797,2318,5023,4884,1884,749
       Other Liabilities 
0
0
0
0
0
0
0
0
6,695
0
0
0
0
0
0
0
0
0
0
0
220,837
196,680
168,651
139,910
123,204
131,490
83,919
22,032
5,342
4,586
5,312
2,665,510
2,601,600
2,510,883
2,439,379
2,385,310
2,389,066
2,286,059
2,168,730
2,119,982
1,963,669
1,872,541
1,825,587
1,733,753
1,671,095
0
0
0
0
0
000001,671,0951,733,7531,825,5871,872,5411,963,6692,119,9822,168,7302,286,0592,389,0662,385,3102,439,3792,510,8832,601,6002,665,5105,3124,5865,34222,03283,919131,490123,204139,910168,651196,680220,837000000000006,69500000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
3,460
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,872
0
0
0
13,334
0
0
0
11,796
0
0
0
0
0
0
0
0
0
00000000011,79600013,33400014,872000000000000000000000003,46000000000
> Total Stockholder Equity
84,324
79,241
108,877
103,181
148,507
118,292
118,376
112,340
118,447
168,012
167,136
225,015
206,135
0
443,455
418,790
364,999
728,545
729,800
708,821
758,701
748,150
1,069,026
1,036,932
1,011,984
899,345
885,659
1,188,222
1,214,249
1,175,755
1,143,367
2,535,281
2,875,658
2,840,041
2,773,263
2,712,083
2,670,355
2,701,462
2,663,473
2,617,383
2,643,362
2,646,589
2,646,898
2,690,351
2,526,026
2,564,604
2,583,948
2,621,560
2,795,566
2,895,008
2,895,0082,795,5662,621,5602,583,9482,564,6042,526,0262,690,3512,646,8982,646,5892,643,3622,617,3832,663,4732,701,4622,670,3552,712,0832,773,2632,840,0412,875,6582,535,2811,143,3671,175,7551,214,2491,188,222885,659899,3451,011,9841,036,9321,069,026748,150758,701708,821729,800728,545364,999418,790443,4550206,135225,015167,136168,012118,447112,340118,376118,292148,507103,181108,87779,24184,324
   Common Stock
110,855
0
122,870
124,381
137,122
137,451
137,460
138,301
139,347
154,372
154,542
156,218
157,274
0
184,416
185,055
185,399
221,779
223,149
223,462
223,928
223,928
233,018
233,192
233,414
235,027
235,583
235,672
236,540
237,348
238,475
272,605
287,282
288,106
290,462
290,929
291,312
291,852
291,912
291,953
292,075
292,592
293,026
293,605
293,604
293,937
293,937
293,937
293,937
293,937
293,937293,937293,937293,937293,937293,604293,605293,026292,592292,075291,953291,912291,852291,312290,929290,462288,106287,282272,605238,475237,348236,540235,672235,583235,027233,414233,192233,018223,928223,928223,462223,149221,779185,399185,055184,4160157,274156,218154,542154,372139,347138,301137,460137,451137,122124,381122,8700110,855
   Retained Earnings -133,080-228,274-403,242-440,792-459,821-496,689-326,905-367,381-366,119-367,205-391,311-345,101-306,881-334,701-297,098-235,224-150,597-109,223-3,907-376,518-340,020-297,779-321,495-343,796-328,620-211,441-186,432-154,553-122,854-112,272-162,048-140,845-139,465-177,317-122,634-97,1420-63,944-42,697-100,107-99,635-94,770-101,599-91,140-90,109-60,079-76,273-66,868-78,117-72,492
   Accumulated Other Comprehensive Income 
45,961
-1,947
52,875
55,073
71,463
70,950
72,056
3,199
994
844
217
-1,723
-1,377
0
-416
-786
-485
-867
-1,057
-1,423
-2,090
-2,059
-2,215
0
-3,014
-2,398
-2,245
-2,239
-2,292
-2,025
-2,240
-2,002
-5,984
-5,582
-5,646
-7,356
-14,096
-13,067
-13,162
-13,194
-11,899
-11,918
-11,806
-11,906
-6,446
-6,505
-6,190
-6,128
-7,091
-2,843
-2,843-7,091-6,128-6,190-6,505-6,446-11,906-11,806-11,918-11,899-13,194-13,162-13,067-14,096-7,356-5,646-5,582-5,984-2,002-2,240-2,025-2,292-2,239-2,245-2,398-3,0140-2,215-2,059-2,090-1,423-1,057-867-485-786-4160-1,377-1,7232178449943,19972,05670,95071,46355,07352,875-1,94745,961
   Capital Surplus 00000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.